(Q35087745)

English

Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study (English)

1 reference

Europe PubMed Central

6 August 2017

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Núria Pérez-Álvarez

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Eugènia Negredo

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Bonaventura Clotet Sala

9

object named as

Bonaventura Clotet

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

3

object named as

Jordi Puig

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Patricia Echeverría

1

object named as

Patricia Echeverría

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

5

object named as

Roger Paredes

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

6

object named as

Guillem Sirera

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

7

object named as

Arelly Ornelas

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

language of work or name

0 references

publication date

4 February 2014

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

e84676

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

copyright license

Creative Commons Attribution 4.0 International

4 February 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913576

8 July 2018

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913576

8 July 2018

Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913576

8 July 2018

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913576

8 July 2018

Simplification of antiretroviral therapy with etravirine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913576

8 July 2018

Clinical pharmacokinetics and pharmacodynamics of etravirine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913576

8 July 2018

Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913576

8 July 2018

Switching strategies to improve lipid profile and morphologic changes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913576

8 July 2018

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913576

8 July 2018

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913576

8 July 2018

Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913576

8 July 2018

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0084676

21 January 2018

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0084676

21 January 2018

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0084676

21 January 2018

Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0084676

21 January 2018

A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0084676

21 January 2018

Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0084676

21 January 2018

A randomized crossover study to compare efavirenz and etravirine treatment.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0084676

21 January 2018

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0084676

21 January 2018

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0084676

21 January 2018

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0084676

21 January 2018

Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0084676

21 January 2018

Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0084676

21 January 2018

Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0084676

21 January 2018

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0084676

21 January 2018

Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913576

27 September 2018

Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913576

27 September 2018

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population

1 reference

https://pubmed.ncbi.nlm.nih.gov/24503952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24503952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0084676

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

2014PLoSO...984676E

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24503952%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35087745&oldid=1962596750"